



Zai Lab Announces Clinical Data to be Presented at ESMO Virtual Congress 2020

September 3, 2020

SHANGHAI and SAN FRANCISCO, Sept. 03, 2020 (GLOBE NEWSWIRE) -- Zai Lab Limited ("Zai Lab") (NASDAQ: ZLAB), an innovative commercial-stage biopharmaceutical company, today announced that detailed clinical data from the NORA Phase 3 study of niraparib have been accepted as a late-breaker oral presentation at the European Society for Medical Oncology (ESMO) 2020 Virtual Congress. Details of the oral presentation are as follows:

Title: Individualized Starting Dose of Niraparib in Chinese Patients with Platinum-Sensitive Recurrent Ovarian Cancer (PSROC): A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial (NORA)

Presentation Number: LBA29

Lecture Time: September 19, 2020, 13:14-13:26 Central European Summer Time

Presenter: Dr. Xiaohua Wu, Professor and Chair of Gynecologic Oncology Department of Fudan University Shanghai Cancer Centre

About Zai Lab

Zai Lab (NASDAQ:ZLAB) is an innovative commercial stage biopharmaceutical company focused on bringing transformative medicines for cancer, infectious and autoimmune diseases to patients in China and around the world. To quickly target the large, fast-growing segments of China's pharmaceutical market and address unmet medical needs, Zai Lab's experienced team has secured partnerships with leading global biopharma companies, generating a broad pipeline of innovative drug candidates. Zai Lab has also built an in-house team with strong drug discovery and translational research capabilities, aiming to establish a global pipeline of proprietary drug candidates against targets in our focus areas. Zai Lab's vision is to become a fully integrated biopharmaceutical company, discovering, developing, manufacturing and commercializing its portfolio in order to impact human health worldwide.

For additional information about the company, please visit www.zailaboratory.com or follow us at www.twitter.com/ZaiLab_Global.

For more information, please contact:

ZAI LAB CONTACTS:

Zai Lab

Billy Cho, CFO

+86 137 6151 2501

billy.cho@zailaboratory.com

Media: Ryo Imai / Robert Flamm, Ph.D.

Burns McClellan, on behalf of Zai Lab

212-213-0006 ext. 315 / 364

rimei@burnsmc.com / rflamm@burnsmc.com

Investors: Pete Rahmer / Mike Zanoni

Endurance Advisors, on behalf of Zai Lab

415-515-9763 / 610-442-8570

prahmer@enduranceadvisors.com / mzanoni@enduranceadvisors.com

Zai Lab Limited



Source: Zai Lab Limited